Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement，make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement．

## CanSino Biologics Inc． <br> 康希諾生物股份公司

（A joint stock company incorporated in the People＇s Republic of China with limited liability）
（Stock code：6185）

## VOLUNTARY ANNOUNCEMENT INITIATION OF PHASE III CLINICAL TRIAL AND COMPLETION OF FIRST PATIENT ENROLLMENT FOR ABSORBED TETANUS VACCINE

This announcement is made by CanSino Biologics Inc．（the＂Company＂）on a voluntary basis．
The Company is pleased to announce that，the phase III clinical trial for the Absorbed Tetanus Vaccine developed by the Company，was officially initiated recently and the first trial patient case has been formally enrolled．

Phase III clinical trial will evaluate the safety and immunogenicity of Absorbed Tetanus Vaccine in population aged above 18 years old，and conduct a randomized，blinded，positive control clinical trial．

The Absorbed Tetanus Vaccine is fermented with animal－free culture medium and safer，and the stable industrial scale processes have been identified．This vaccine is mainly used for non－neonatal tetanus prevention，which will further enrich the Company＇s product pipeline and enhance its core competitiveness．

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company．

By order of the Board CanSino Biologics Inc． Xuefeng YU
Chairman
Hong Kong，March 20， 2024
As of the date of this announcement，the board of directors of the Company comprises Dr．Xuefeng YU，Dr．Shou Bai CHAO and Ms．Jing WANG as executive directors，Ms．Nisa Bernice Wing－Yu LEUNG as a non－executive director，and Mr．Shuifa GUI，Mr．Jianzhong LIU and Mr．Yiu Leung Andy CHEUNG as independent non－executive directors．

